The nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors in the treatment of HIV infections (AIDS).
作者： Erik De Clercq
DOI: 10.1016/B978-0-12-405880-4.00009-3
关键词: Discovery and development of non-nucleoside reverse-transcriptase inhibitors 、 Nucleoside Reverse Transcriptase Inhibitor 、 Virology 、 Mechanism of action 、 Protease 、 Reverse transcriptase 、 Acquired immunodeficiency syndrome (AIDS) 、 Medicine 、 Drug 、 HIV Protease Inhibitor 、 Pharmacology
摘要: The majority of the drugs currently used for treatment HIV infections (AIDS) belong to either following three classes: nucleoside reverse transcriptase inhibitors (NRTIs), nonnucleoside (NNRTIs), and protease (PIs). At present, there are 7 NRTIs, 5 NNRTIs, 10 PIs approved clinical use. They discussed from viewpoints: (i) chemical formulae; (ii) mechanism action; (iii) drug combinations; (iv) aspects; (v) preexposure prophylaxis; (vi) prevention mother-to-child transmission; (vii) their use in children; (viii) toxicity; (ix) adherence (compliance); (x) resistance; (xi) new or (pre)clinical development; (xii) prospects a "cure" disease.
sci-hub.se 参考文章(202)
Laurence Bequet, Ida Viho, Didier Koumavi Ekouevi, Patricia Fassinou, Renaud Becquet, Christiane Welffens-Ekra, François Rouet, Apollinaire Horo, François Dabis, Valériane Leroy, Charlotte Sakarovitch, Laurence Dequae-Merchadou, Chrisitine Rouzioux, Field efficacy of zidovudine, lamivudine and single-dose nevirapine to prevent peripartum HIV transmission. AIDS. ,vol. 19, pp. 309- 318 ,(2005)
Jonathan Z Li, Roger Paredes, Heather J Ribaudo, Evguenia S Svarovskaia, Michael J Kozal, Katherine H Hullsiek, Michael D Miller, David R Bangsberg, Daniel R Kuritzkes, None, Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure. AIDS. ,vol. 26, pp. 185- 192 ,(2012) , 10.1097/QAD.0B013E32834E9D7D
Bonaventura Clotet, José A Muñoz-Moreno, Carmina R Fumaz, Eugènia Negredo, Marian González-García, José Moltó, Maria J Ferrer, Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates, and management. A neurobehavioral review. Aids Reviews. ,vol. 11, pp. 103- 109 ,(2009)
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration The Lancet. ,vol. 371, pp. 1417- 1426 ,(2008) , 10.1016/S0140-6736(08)60423-7
BJ Welzen, T Mudrikova, JE Arends, AIM Hoepelman, No increased risk of hepatotoxicity in long-term use of nonnucleoside reverse transcriptase inhibitors in HIV-infected patients Hiv Medicine. ,vol. 13, pp. 448- 452 ,(2012) , 10.1111/J.1468-1293.2012.00995.X
Jonathan M. Schapiro, Robert W. Shafer, HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. Aids Reviews. ,vol. 10, pp. 67- 84 ,(2008)
Emanuele Focà, Diego Ripamonti, Davide Motta, Carlo Torti, Unboosted atazanavir for treatment of HIV infection: rationale and recommendations for use. Drugs. ,vol. 72, pp. 1161- 1173 ,(2012) , 10.2165/11631070-000000000-00000
Chris Tantillo, Jianping Ding, Alfredo Jacobo-Molina, Raymond G. Nanni, Paul L. Boyer, Stephen H. Hughes, Rudi Pauwels, Koen Andries, Paul A.J. Janssen, Edward Arnold, Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance Journal of Molecular Biology. ,vol. 243, pp. 369- 387 ,(1994) , 10.1006/JMBI.1994.1665
Jordi Casabona, Ard van Sighem, James M Robins, Santiago Pérez-Hoyos, Loveleen Bansi, Luigia Elzi, Georgia Vourli, Giota Touloumi, Janet Tate, Roger Logan, Julia del Amo, Andrew Phillips, Jonathan A C Sterne, Heiner C Bucher, Anna Esteve, Frank de Wolf, Santiago Moreno, Dominique Costagliola, Sophie Abgrall, Lauren E Cain, Amy Justice, Rémonie Seng, Miguel A Hernán, Sara Lodi, Caroline Sabin, Roberto Muga, Laurence Meyer, The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study AIDS. ,vol. 26, pp. 1691- 1705 ,(2012) , 10.1097/QAD.0B013E328354F497
Erik De Clercq, Tenofovir: quo vadis anno 2012 (where is it going in the year 2012)? Medicinal Research Reviews. ,vol. 32, pp. 765- 785 ,(2012) , 10.1002/MED.21267